uniQure N.V. (QURE) vs Zenas BioPharma, Inc. (ZBIO)
A side-by-side comparison of uniQure N.V. and Zenas BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
QURE
uniQure N.V.
$23.06HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZBIO
Zenas BioPharma, Inc.
$26.94HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — QURE vs ZBIO
growth of $100 · dividends reinvested · last 2yQURE +311.6% (+102.9%/yr)ZBIO +54.9% (+24.4%/yr)QURE compounded faster over this window
QURE ZBIO
QURE vs ZBIO: by the numbers
- •ZBIO is the larger company ($1.70B vs $1.60B market cap).
- •Both run net losses; QURE's is the smaller (-1350.73% vs -48438.40% net margin).
Metrics side by side
Valuation
| Metric | QURE | ZBIO |
|---|---|---|
| P/S ratio | 85.67 | 1700.81 |
| P/B ratio | 4.94 | 6.88 |
Profitability
| Metric | QURE | ZBIO |
|---|---|---|
| Gross margin | 89.53% | 100.00% |
| Operating margin | -1166.77% | -2113.85% |
| Net margin | -1350.73% | -48438.40% |
| ROE | -77.83% | -196.03% |
| ROIC | -22.55% | -74.69% |
Growth (annualized)
| Metric | QURE | ZBIO |
|---|---|---|
| Revenue CAGR (5Y) | -48.20% | N/A |
| Total return CAGR (5Y) | -6.16% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.